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Background: Interferon stimulated genes (ISGs) - Mx1, OAS1
and PKR (EIF2AK2) play a key role in antiviral response against
HCV infection. It is suggested that ISGs pre-activation is associ-
ated with anti-HCV treatment failure. Moreover, it was observed
that interferon may stimulate transcription of TP53gene. The aim
of this prospective study was to examine the association between
Mx1, OAS1, PKR (EIF2AK2) and TP53 expression and response to
pegIFN+RBV treatment in CHC patients.
Methods&Materials:Genomic RNAwas obtained from35 CHC
patients (genotype1b) treatedwithpegIFN-+RBV.Mx1,OAS1,PKR
and TP53 expression levels were quantiﬁed by real-time PCR using
TaqMan probes. Serum HCV-RNA was measured by quantitative
RT-PCR with speciﬁc primers from 5’noncoding region. Analyses
were performed before pegIFN+RBV administration and then at 4.
and 12. week of treatment.
Results: RVR and cEVR was achieved by 13 (37.1%) and 10
(28.6%) patients, respectively. 12 (34.3%) did not response to
pegIFN+RBV treatment during 12 weeks (PNR). The mean values of
baseline viral loads were comparable in RVR, cEVR and PNR group
(6.7, 7.3 and 3.5x104 IU/ml, respectively). Median expression levels
of classical ISG (Mx1,OAS1,PKR), butnotTP53: increasedduringCHC
treatment; was higher in RVR compared to cEVR and PNR group
before therapy; more noticeable increased in cEVR and PNR and
than in RVR patients at week 4., was stable or poorly decreased
in RVR, was stable or poorly increased in cEVR and noticeable
decreased in PNR group between week 4. and 12. of therapy.
Conclusion: Increase in ISGs expression at week 4. of therapy
mightdependonbaselineHCV-RNA level. ISGs expressionmaypre-
dict outcome of pegIFN + RBV treatement – pre-activation of the
endogenous interferon system is associated with RVR and thereby
with high likehood of achieving SVR. Treatment failure during the
ﬁrst 12 weeks of anti-HCV therapy (PNR) may be related to notice-
able decrease in ISG expression betweenweek4. and12. There is no
association between TP53 expression and interferon action during
treatment of CHC patients.
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Background: Identiﬁcation of molecular markers playing role
in predicting anti-HCV treatment outcomewould facilitate therapy
optimizing. GWAShas demonstrated that genetic polymorphismat
rs12979860 (C/T) near IL28B gene is a strong predictor of Sustained
Virological Response (SVR) in chronic hepatitis C (CHC) patients
treatedwith pegylated interferon and ribavirin (pegIFN- +RBV).
Moreover, monitoring viral kinetics can help identify patients with
high chances of treatment success. The aim of this study was to
examine predictive value of IL28B SNP rs12979860 (C/T) for on-
treatment virological response in Polish CHC patients treated with
pegIFN- and RBV.
Methods & Materials: The study involved 35 CHC patients
(HCV genotype 1b). To determine treatment effect, serum HCV-
RNA was measured on the ﬁrst day of therapy and then after 4 and
12 weeks of treatment by one-step quantitative RT-PCR. Genomic
DNA, isolated from peripheral blood lymphocytes, was used for
IL28B rs12979860 (C/T) genotyping by High Resolution Melting
(HRM) method.
Results:ResultswereconﬁrmedbyDNAsequencing. 13patients
(37.1%) became HCV RNA negative at week 4. (RVR - Rapid Virolo-
gical Response) and 10 (28.6%) at week 12. (cEVR - complete Early
Virological Response). 12 patients (34.3%) did not achieve viro-
logical response until 12. weeks (PNR - Primary Non-Response).
The mean baseline viral load values were comparable among three
groups -6.69x104 IU/mlvs7.32x104 IU/mlvs3.51x104IU/ml inRVR,
cEVR and PNR group, respectively. The rs12979860 CC, CT and TT
genotypes were found in 8 (22.9%), 23 (65.7%), 4 (11.4%) patients,
respectively. Among patients with genotype CC, 75% achieved RVR
and 25% achieved cEVR. Among CT genotype, RVR, cEVR and PNR
wereobserved in30.5%, 30.5%and39%ofpatients, respectively. 25%
of patients with the genotype TT achieved cEVR and 75% achieved
PNR. Favorable CC was not observed in PNR and unfavorable TT
genotype was not observed in RVR group.
Conclusion:The results conﬁrmthatIL28Brs12979860C/Tpoly-
morphism may predicts virological response in CHC during early
phase of pegIFN + RBV treatment.
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